{"schema_version":"secwatch.filing_event.v1","accession":"0001178913-26-001724","form_type":"8-K","ticker":"LFWD","cik":"0001607962","company_name":"Lifeward Ltd.","filed_at":"2026-03-25T23:59:59+00:00","discovered_at":"2026-05-14T18:02:35.632937+00:00","generated_at":"2026-05-15T09:01:15.677432+00:00","sec_items":["2.01","1.01","3.02","5.02","9.01"],"event_type":"m_and_a","sentiment":"neutral","materiality_score":0.9,"calibrated_materiality_score":0.9,"confidence":"high","headline":"Lifeward completes acquisition of Oratech Pharma, issues shares and convertible notes","bullets":["Lifeward completed acquisition of Oratech Pharma on March 25, 2026, issuing 2,256,476 ordinary shares and pre-funded warrants to Oramed.","Issued $10,000,000 aggregate principal amount of senior secured convertible notes and warrants in a private placement.","Directors Dr. John William Poduska and Randel Richner resigned effective March 25, 2026.","Appointed Nadav Kidron, Miriam Kidron, and Yehuda Reznick as new directors, expanding board from five to eight.","Entered into a First Amendment and Assignment to assign Oratech Pharma rights to Oratech Ltd."],"urls":{"canonical":"https://secwatch.observer/filing/0001178913-26-001724","json":"https://secwatch.observer/filing/0001178913-26-001724.json","markdown":"https://secwatch.observer/filing/0001178913-26-001724.md","text":"https://secwatch.observer/filing/0001178913-26-001724.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1607962/000117891326001724/0001178913-26-001724-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1607962/000117891326001724/zk2634956.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud","generated_at":"2026-05-15T09:01:15.677432+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"85314fd3163beb52139fcb9eb840058703b36048","claim":"Lifeward Ltd. issued convertible note to Oramed and certain investors for $10,000,000.00 aggregate principal amount.","evidence_excerpt":"On March 25, 2026, the Company issued: (i) $10,000,000.00 aggregate principal amount senior secured convertible notes (the “Initial Notes”), convertible into Ordinary Shares, and (ii) accompanying warrants to purchase Ordinary Shares (the “Initial Warrants”).","evidence_source":"SEC 8-K Item 3.02/3.03","evidence_url":"https://www.sec.gov/Archives/edgar/data/1607962/000117891326001724/0001178913-26-001724-index.htm","confidence":0.9,"family_label":"Equity Issuances","details":[{"label":"Security","value":"convertible note"},{"label":"Purchaser","value":"Oramed and certain investors"},{"label":"Consideration","value":"$10,000,000.00 aggregate principal amount"}],"fact_type":"equity_issuance"},{"claim_id":"bb36ec74895e02fbb716ecee5c71129b0fac0994","claim":"Lifeward Ltd. issued warrant to Oramed and certain investors.","evidence_excerpt":"On March 25, 2026, the Company issued: (i) $10,000,000.00 aggregate principal amount senior secured convertible notes (the “Initial Notes”), convertible into Ordinary Shares, and (ii) accompanying warrants to purchase Ordinary Shares (the “Initial Warrants”).","evidence_source":"SEC 8-K Item 3.02/3.03","evidence_url":"https://www.sec.gov/Archives/edgar/data/1607962/000117891326001724/0001178913-26-001724-index.htm","confidence":0.9,"family_label":"Equity Issuances","details":[{"label":"Security","value":"warrant"},{"label":"Purchaser","value":"Oramed and certain investors"}],"fact_type":"equity_issuance"},{"claim_id":"c5456fe7149710d4eba9fd99e93dcc11d2882441","claim":"Lifeward Ltd. completed an acquisition involving Oramed Pharmaceuticals, Inc. (closed 2026-03-25).","evidence_excerpt":"On March 25, 2026, the Company completed its acquisition of Oratech in accordance with the terms of the Share Purchase Agreement.","evidence_source":"SEC 8-K Item 2.01/5.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1607962/000117891326001724/0001178913-26-001724-index.htm","confidence":0.9,"family_label":"M&A Transactions","details":[{"label":"Action","value":"acquisition"},{"label":"Counterparty","value":"Oramed Pharmaceuticals, Inc."},{"label":"Closing","value":"2026-03-25"}],"fact_type":"ma_transaction"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}